The baseline characteristics and genomic risk characterization of the genomic study cohort of the ALL06 study
| . | Patient characteristics . | Protocol risk stratification . |
|---|---|---|
| Total | N = 57 | |
| Age, y; median [range] | 22 [16-38] | |
| Female; n (% of total) | 15 (26%) | |
| BMI (kg/m2); median [range] | 24.8 [15.5-50.6] | |
| ≥30 | n = 10 | |
| <30 | n = 47 | |
| MRD at TP1 | N = 49 | |
| Negative; n (%) | 5 (10%) | |
| Positive; n (%) | 44 (90%) | |
| MRD at TP2 | N = 49 | |
| Negative; n (%) | 24 (49%) | |
| Positive; n (%) | 25 (51%) | |
| B-ALL | N = 40 | |
| Adverse genomic risk; n (%) | 25 (63%) | 16/23 high or very high, 3 medium-high, and 4 standard/medium risk∗ |
| Standard genomic risk; n (%) | 15 (38%) | 2/15 high or very-high, 4 medium-high, and 8 standard/medium risk |
| T-ALL | N = 17 | |
| Adverse genomic risk; n (%) | 10 (59%) | 6/9 high or very-high, 1 medium-high, 2 standard/medium risk† |
| Standard genomic risk; n (%) | 7 (41%) | 6/6 standard or medium risk† |
| . | Patient characteristics . | Protocol risk stratification . |
|---|---|---|
| Total | N = 57 | |
| Age, y; median [range] | 22 [16-38] | |
| Female; n (% of total) | 15 (26%) | |
| BMI (kg/m2); median [range] | 24.8 [15.5-50.6] | |
| ≥30 | n = 10 | |
| <30 | n = 47 | |
| MRD at TP1 | N = 49 | |
| Negative; n (%) | 5 (10%) | |
| Positive; n (%) | 44 (90%) | |
| MRD at TP2 | N = 49 | |
| Negative; n (%) | 24 (49%) | |
| Positive; n (%) | 25 (51%) | |
| B-ALL | N = 40 | |
| Adverse genomic risk; n (%) | 25 (63%) | 16/23 high or very high, 3 medium-high, and 4 standard/medium risk∗ |
| Standard genomic risk; n (%) | 15 (38%) | 2/15 high or very-high, 4 medium-high, and 8 standard/medium risk |
| T-ALL | N = 17 | |
| Adverse genomic risk; n (%) | 10 (59%) | 6/9 high or very-high, 1 medium-high, 2 standard/medium risk† |
| Standard genomic risk; n (%) | 7 (41%) | 6/6 standard or medium risk† |